The FDA has released new draft guidance for industry on refuse-to-file (RTF) action taken by the FDA. The document seeks to clarify circumstances under which the FDA’s Center for Drug Evaluation and Research (CDER) may refuse to file a new drug application (NDA), supplemental NDA, or a Biologics License Application (BLA), or supplemental BLA for a product regulated by CDER.
The FDA has released new draft guidance for industry on refuse-to-file (RTF) action taken by the FDA. The document seeks to clarify circumstances under which the FDA’s Center for Drug Evaluation and Research (CDER) may refuse to file a new drug application (NDA), supplemental NDA, or a Biologics License Application (BLA), or supplemental BLA for a product regulated by CDER. The guidance highlights the importance of submitting a complete application to minimize the chance of an RTF action.
The FDA typically either files an NDA or BLA within 60 days of receipt or informs the applicant of an RTF action. The filing of an application signals that the agency has made a threshold determination that the application’s content is sufficiently complete to permit a thorough review of its merits.
FDA regulations describe the possibility that the agency will consider an application incomplete if it is obviously deficient in a way that will make a review impossible, but the agency acknowledges in its new draft guidance that the administrative threshold to determine completeness has increased in recent years. The guidance points to pre-submission meetings between applicants and the FDA as opportunities to reach agreements regarding the content of a complete application, as well as agreement on submission of minor components that may be submitted within a 30-day period after the original application is submitted (though a rolling review period is available for fast-track designations). These additional submissions can add to the complexity of determining an application’s completeness. However, timely reviews of applications—provided for under user fee act agreements—make it imperative that the agency exercise its RTF authority when necessary to optimize the applicant’s and the FDA’s time and resources.
The types of application deficiencies that may result in an RTF action by day 60 are as follows:
Within 30 days after an RTF notification, an applicant can request an informal conference with the FDA to discuss whether the agency should file an application despite the RTF action.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
FDA Draft Guidance Removes Switching Study Requirements for Biosimilar Interchangeability
June 20th 2024The FDA has issued an update to its guidance on requiring switching study data for biosimilars to be granted interchangeability, citing new science that shows these studies aren’t needed to establish biosimilar safety.
British Columbia’s Biosimilar Switching Program Saves $732 Million in 5 Years
June 18th 2024British Columbia's 2019 Biosimilars Initiative, which transitioned over 40,000 patients from costly reference biologics to biosimilars, saved around $732 million in 5 years, maintained comparable health outcomes, and reinvested the savings to improve the province's public payer program.